Prescription medicine
Riboflavin 5-phosphate ophthalmic Brand names: Epioxa, Photrexa
Riboflavin 5-phosphate ophthalmic (Epioxa) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
- A presentation discontinued
Check it at the source: the riboflavin 5-phosphate ophthalmic FDA label on DailyMed (effective July 24, 2026); every riboflavin 5-phosphate ophthalmic label on DailyMed.
Highlights of the record
FDA label of July 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usagePHOTREXA ® VISCOUS and PHOTREXA ® are indicated for use in corneal collagen cross-linking in combination with the KXL ® System for the treatment of PHOTREXA VISCOUS and PHOTREXA are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus ( 1.1 ) and corneal ectasia following refractive surgery ( 1.2 ).
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 4 through July 30, 2026
What is riboflavin 5-phosphate ophthalmic used for?
From the label: indications and usagePHOTREXA ® VISCOUS and PHOTREXA ® are indicated for use in corneal collagen cross-linking in combination with the KXL ® System for the treatment of PHOTREXA VISCOUS and PHOTREXA are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus ( 1.1 ) and corneal ectasia following refractive surgery ( 1.2 ). 1.1 Progressive Keratoconus 1.2 Corneal Ectasia Following Refractive Surgery
Source: FDA drug label (Photrexa Cross-linking Kit), Glaukos Corporation, effective July 24, 2026 (SPL set f82cfe92-1a24-11e3-8ffd-0800200c9a66), via openFDA; the full label on DailyMed
Is there a generic for riboflavin 5-phosphate ophthalmic (Epioxa)?
No generic riboflavin 5-phosphate ophthalmic is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Is riboflavin 5-phosphate ophthalmic in shortage?
No riboflavin 5-phosphate ophthalmic presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated January 20, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03) | Glaukos Corporation | To Be Discontinued | January 20, 2026 |
Every riboflavin 5-phosphate ophthalmic presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the riboflavin 5-phosphate ophthalmic label say about other medicines?
The riboflavin 5-phosphate ophthalmic label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Benzalkonium | contraindications | Hypersensitivity EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. |
Check riboflavin 5-phosphate ophthalmic against other medicines
Source: FDA drug label (Photrexa Cross-linking Kit), Glaukos Corporation, effective July 24, 2026 (SPL set f82cfe92-1a24-11e3-8ffd-0800200c9a66), via openFDA; the full label on DailyMed
What do FAERS reports show for riboflavin 5-phosphate ophthalmic?
The FDA Adverse Event Reporting System holds 4 reports that list riboflavin 5-phosphate ophthalmic among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Riboflavin 5-phosphate ophthalmic side effects
- the label's list beside FAERS reports
- Riboflavin 5-phosphate ophthalmic shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other